Cargando…
Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function
Cardiometabolic disorders including obesity, diabetes and cardiovascular disease are among the most severe health problems worldwide. DPP4 enzymatic inhibitors were first developed as anti-diabetic reagents which preserve incretin hormones and promote post-prandial insulin secretion. It's been...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ireland Ltd.
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114201/ https://www.ncbi.nlm.nih.gov/pubmed/26142202 http://dx.doi.org/10.1016/j.ijcard.2015.06.076 |